Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

著者: Michael A. Matthay, Carolyn S. Calfee, Hanjing Zhuo, Bruce Thompson, Jennifer G. Wilson, Joseph E. Levitt, Angela J Rogers, Jeffrey E. Gotts, Jeanine P. Wiener-Kronish, Ednan K. Bajwa, Michael P. Donahoe, Bryan J. McVerry, Luis A. Ortiz, Matthew C. Exline, John W. Christman, Jason Abbott, Kevin Delucchi, Lizette Caballero, Melanie McMillan, David H. McKenna, Kathleen D. Liu - The Lancet 2018 被引用: 632